New Alzheimer’s Drug Slows Cognitive Decline by 35%

New Alzheimer’s Drug Slows Cognitive Decline by 35%

Eli Lilly’s donanemab delivers promising Phase 3 data, raising hopes for earlier intervention therapies. A major Alzheimer’s study released this week confirmed that donanemab, Eli Lilly’s monoclon...